TTNP - Titan Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
-0.0672 (-3.61%)
As of 3:47PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.8600
Bid1.7800 x 2900
Ask1.7900 x 2200
Day's Range1.7600 - 1.8800
52 Week Range0.1720 - 2.4500
Avg. Volume1,675,221
Market Cap23.299M
Beta (3Y Monthly)0.29
PE Ratio (TTM)N/A
EPS (TTM)-2.6970
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.90
Trade prices are not sourced from all markets
  • ACCESSWIRE28 days ago

    4 Healthcare Stocks Looking To Kick Off A Strong Week

    CORAL GABLES, FL / ACCESSWIRE / February 25, 2019 / The future success of the healthcare stock market will be determined by whether companies in the industry are aptly prepared to meet the growing demands for better healthcare. Medical professionals are now advocating for legislation in favor of legalizing marijuana because of the list of health benefits afforded to those who use medicinal cannabis. TSX: ACB), and Actinium Pharmaceuticals Inc (NYSE American: ATNM) represent four healthcare companies focused on improving the quality of life for their patients.

  • Titan Pharmaceuticals Partners With AllianceRx Walgreens Prime Specialty Pharmacy To Expand Patient Access To Probuphine®
    PR Newswire28 days ago

    Titan Pharmaceuticals Partners With AllianceRx Walgreens Prime Specialty Pharmacy To Expand Patient Access To Probuphine®

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced the execution of a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment with Probuphine (buprenorphine) implant, Titan's unique six-month maintenance treatment for opioid use disorder (OUD) in eligible patients. Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model, where a specialty pharmacy such as AllianceRx Walgreens Prime carries inventory, directly handles the subsequent patients' insurance billing and payment processes, and ships to the health care provider as prescribed.

  • Zacks Small Cap Researchlast month

    TTNP: Shipments Spike in 2H:18

    We have now had more than two full quarters of in-house management of Probuphine commercialization by Titan Pharmaceuticals, Inc. (TTNP) and indications are that shipment trends are strong. Since the company had their licenses returned in late May 2018 Titan has implemented a new strategy to grow sales for the innovative implant Probuphine, which is intended for maintenance treatment in patients that are stable on a transmucosal buprenorphine product. In a release last week the company highlighted a 20% sequential increase in shipments in the second half of the year.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks Looking To Start February Off Strong

    With the advent of new approaches to medical care, as well as innovative medical technologies coming out of the healthcare industry, news surrounding innovative companies putting their skills to the test in the has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Titan Pharmaceuticals Inc (TTNP), Aileron Therapeutics Inc (ALRN), Enochian Biosciences Inc (ENOB) represent four healthcare stocks setting the pace on Friday afternoon. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Why Titan Pharmaceuticals Is Soaring Today
    Market Realist2 months ago

    Why Titan Pharmaceuticals Is Soaring Today

    Why Titan Pharmaceuticals Is Soaring TodayStock price movementsOn January 31, 2019, Titan Pharmaceuticals (TTNP) issued a press release announcing a 20% rise in shipments of its Probuphine implant used to treat opioid use disorder. The positive

  • How Many Insiders Bought Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Shares?
    Simply Wall St.2 months ago

    How Many Insiders Bought Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Shares?

    Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. We often see insiders buying up shares in Read More...

  • Why Titan Pharmaceuticals Stock Is Skyrocketing Today
    InvestorPlace2 months ago

    Why Titan Pharmaceuticals Stock Is Skyrocketing Today

    Titan Pharmaceuticals stock was soaring Friday on news concerning the relaunch of Probuphine. Source: Titan Pharmaceuticals Titan Pharmaceuticals' (NASDAQ:TTNP) Probuphine is a subdermal implant that delivers buprenorphine to a patient. This implant only requires a single procedure to be put in place and works for six months. Titan Pharmaceuticals notes that Probuphine is used to treat adults that are suffering from opiod addiction. This includes addition from both prescription and illegal versions of the drug. It got approval from the U.S. Food and Drug Administration in May 2016 and is the only implant of its kind for treating this type of addiction. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The good news for Titan Pharmaceuticals is that a recent relaunch of Probuphine is performing well. The company says that it has seen a double digit increase in shipments of the device during the period of its relaunch, which was in mid-June 2018. Titan Pharmaceuticals stock is also getting a boost from the company saying that shipments of Probuphine have continued to increase 20% sequentially for the rest of 2018. It will provide more details about this when it releases its earnings report for the fourth quarter of 2018 in March. * 7 S&P 500 Stocks to Buy That Tore Up Earnings The news release that has Titan Pharmaceuticals stock on the move today also includes other details about the Probuphine relaunch. Among these are it acquiring commercial and medical affairs personnel for all targeted regions to help the treatment grow. It also has a government relations firm that is helping with a lobbying plan for Probuphine. TTNP stock was up 33% as of Friday morning. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 of the Best Stocks to Buy for a Dovish Federal Reserve * 5 Best Fidelity ETFs for Retirement Savers * 7 Blue-Chip Stocks That Could Lead the Market Higher As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post Why Titan Pharmaceuticals Stock Is Skyrocketing Today appeared first on InvestorPlace.

  • ACCESSWIRE2 months ago

    Pipeline Update, Review and Progress Titan Pharmaceuticals, Inc.

    NEW YORK, NY / ACCESSWIRE / February 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Titan Pharmaceuticals Reports Positive Initial Results Of Probuphine® Relaunch
    PR Newswire2 months ago

    Titan Pharmaceuticals Reports Positive Initial Results Of Probuphine® Relaunch

    SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), today provided an update on the U.S. commercial relaunch of Probuphine (buprenorphine) implant, its unique six-month treatment for Opioid Use Disorder (OUD). Titan also reengaged with health care providers who had previously treated patients with Probuphine, providing retraining and medical liaison assistance where needed and creating an integrated sales strategy to support them and their office staff. Based on preliminary information, total shipments of Probuphine during the rest of the year increased sequentially by over 20%.  Titan expects to provide more details in its fourth quarter and full-year 2018 financial results, which it expects to release in late March 2019.

  • Titan Pharmaceuticals Announces Reverse Stock Split
    PR Newswire2 months ago

    Titan Pharmaceuticals Announces Reverse Stock Split

    SOUTH SAN FRANCISCO, Calif. , Jan. 24, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a commercial stage company developing proprietary therapeutics using its ProNeura™ long-term continuous ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of TTNP earnings conference call or presentation 14-Nov-18 9:15pm GMT

    Q3 2018 Titan Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE3 months ago

    Alternatives to Watch

    HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Below are several companies positioning themselves to be a viable opioid alternative. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), INSYS Therapeutics, ...

  • GlobeNewswire4 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Zacks Small Cap Research4 months ago

    TTNP: New CCO Implementing Targeted Strategy

    Titan Pharmaceuticals, Inc. (TTNP) reported third quarter 2018 results on November 14th in a press release and in a subsequently filed 10-Q. During the period, Titan recorded total revenues of $1.7 million compared to $40 thousand in 3Q:17. The $244,000 in Titan-generated Probuphine sales compares to 2Q:18’s $75,000, which was for a partial period.

  • Associated Press4 months ago

    Titan Pharmaceuticals: 3Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 11 cents per share. The specialty pharmaceutical company posted revenue of $1.7 million in the period. In the final minutes of trading on Wednesday, ...

  • Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results
    PR Newswire4 months ago

    Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing and commercializing proprietary therapeutics for the treatment of select chronic ...

  • Titan Pharmaceuticals Schedules Conference Call To Review Third Quarter 2018 Financial Results
    PR Newswire5 months ago

    Titan Pharmaceuticals Schedules Conference Call To Review Third Quarter 2018 Financial Results

    Management Team to Host Conference Call Nov. 14 at 4:15 p.m. EST / 1:15 p.m. PST SOUTH SAN FRANCISCO, Calif. , Nov. 8, 2018 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing ...

  • ACCESSWIRE5 months ago

    Biotech Stocks and the Midterm Elections

    HENDERSON, NV / ACCESSWIRE / November 7, 2018 / Midterm elections are expected to result in a split Congress, which should increase predictability for the biotech industry, and prevent, what some see as disruptive, government dictated pricing, less likely than if there is a Congress controlled by one party. Propanc Biopharma, Inc. (PPCB) is one biotech firm you should look at today. The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer.

  • ACCESSWIRE5 months ago

    3 Stocks To Watch As Healthcare Market Evolves

    CORAL GABLES, FL / ACCESSWIRE / November 5, 2018 / Healthcare companies are taking a new and novel approach the health tech in the form of new innovation that takes the guesswork out of tracking health & reporting results. Furthermore, new digital screening technology is allowing both patients and physicians to better understand many different health issues, more clearly. Things like Wireless Healthcare are highly ambitious with the presence of various players with current and future market outlook in the developed and emerging markets.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 5, 2018 / Conatus Pharmaceuticals and Titan Pharmaceuticals were both seeing gains in Friday’s trading session. There was no news to explain Titan shares jumping but Conatus reported third quarter results and an update on its trials last week. Conatus Pharmaceuticals Inc. shares closed up 19.63% on about 1.8 million shares traded on Friday.

  • ACCESSWIRE5 months ago

    Surge In Healthcare Growth Sees Rally In These 3 Stocks On Friday

    CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / Over the last few days, prices of the iShares Nasdaq Biotech ETF (IBB) as well as the SPDR Healthcare ETF (XLV) have recovered from previous lows this week. Premier Health Group, Inc. (PHGRF)(PHGI.CN) saw its shares trade higher on Thursday. Shares of Premier Health Group, Inc. (PHGRF)(PHGI.CN) have begun to trade on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol PHGRF in late October, and are now Depository Trust Company eligible, effective Oct. 22, 2018.

  • ACCESSWIRE5 months ago

    3 Healthcare Stocks that Could Move on Industry Growth

    CORAL GABLES, FL / ACCESSWIRE / October 30, 2018 / According to the MarketsAndMarkets* report "Healthcare IT Market by Product (EHR, RIS, PACS, VNA, CPOE, HIE, Telehealth, Healthcare Analytics, Population Health Management, Supply Chain Management, CRM, Fraud Management, Claims Management) End User (Provider, Payer) - Global Forecast to 2021", the market for healthcare IT is expected to reach $280.25 Billion by 2021 at a CAGR of 15.9% during the forecast period. HealthVue is a group of four Greater Vancouver-based fully integrated, paperless and electronic-medical-record-based medical clinics with a 10-year history, 22 healthcare professionals and over 100,000 active patients.

  • ACCESSWIRE5 months ago

    These 3 Stocks Are Moving Higher This Month

    Believe it or not, there are stocks focusing on healthcare that have managed to hit new highs this month including Premier Health Group, Inc. (PHGRF)(PHGI.CN), Titan Pharmaceuticals (TTNP), and Amneal Pharmaceuticals Inc. (AMRX). Premier Health Group, Inc. (PHGRF)(PHGI.CN), has managed to hit trading levels as high as CAD$0.88 this month. The company announced that just this week its common shares that are traded on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol "PHGRF," are now Depository Trust Company eligible.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Titan Pharmaceuticals and Amarin Corporation

    NEW YORK, NY / ACCESSWIRE / October 22, 2018 / U.S. equities finished mostly lower on Friday as earlier gains due to upbeat corporate earnings were hamstrung by a weakness in housing sales. According to ...